Gentian Diagnostics ASA (DE:6FK) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gentian Diagnostics ASA has been granted a European patent for a novel reference method to improve accuracy in diagnostic assays, specifically for NT-proBNP concentration in blood samples. This mass spectrometry-based method will help harmonize NT-proBNP measurements, offering potential benefits to healthcare providers and patients. The company specializes in immunoassays and provides diagnostic reagents globally from its headquarters in Norway.
For further insights into DE:6FK stock, check out TipRanks’ Stock Analysis page.